Current line of management should focus on:
Culture-directed antibiotics (most important)
For MDR Acinetobacter, treatment must be based on sensitivity report—not empirical escalation. Depending on susceptibility, options may include ampicillin-sulbactam, carbapenems (if susceptible), or polymyxins like colistin/polymyxin B, sometimes with inhaled colistin in pneumonia cases.
Source control
Repeat cultures (tracheal aspirate/BAL, blood, urine if needed)
Rule out:
line infection
lung abscess
empyema
secondary fungal infection
Respiratory rehab
Aggressive chest physiotherapy
Nebulisation
Suction protocol
Humidification
Gradual trach weaning assessment
Nutrition
High-protein feeding
Correct
albumin/
electrolytes
Glycemic control
Neuro/swallow evaluation
Dysphagia after prolonged intubation/trach is common
Speech/swallow therapy can help
2) Possible changes in treatment
If “no significant improvement”:
Recheck antibiotic sensitivity report
Check whether organism is colonization vs active infection
CT chest if not already done
Evaluate for:
ARDS/fibrosis
recurrent aspiration
occult infection focus
Infectious disease + Pulmonary/Critical Care opinion together
3) Prognosis
Guarded—but not hopeless.
Recovery depends on: Good signs
Off ventilator / only trach support
Stable BP without vasopressors
Improving oxygen need
Kidney/
liver okay
Conscious/cooperative
Poor prognostic signs
Persistent fever/sepsis
Shock
Renal failure
Rising inflammatory markers
Repeat cultures still positive
Muscle wasting / bed bound state
Many such patients recover slowly over weeks to months, especially respiratory and swallowing function.
If you can share:
culture sensitivity report,
current antibiotics,
oxygen requirement,
kidney function/
creatinine,
whether patient is conscious and moving limbs